The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 29, 2024

Filed:

Oct. 15, 2019
Applicant:

The Medical College of Wisconsin, Inc., Milwaukee, WI (US);

Inventor:

Michael A. James, Big Bend, WI (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/30 (2013.01); A61K 47/6803 (2017.08); A61K 47/6851 (2017.08); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/52 (2013.01); C07K 2317/622 (2013.01);
Abstract

Provided herein are therapeutic agents having specificity for human CLPTM1L/CRR9 polypeptide, including therapeutic agents comprising one or more CLPTM1L-targeting agents, compositions comprising such therapeutic agents, and methods of using such compositions for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1L/CRR9 protein dysfunction (e.g., pathogenic production, modification, or function). In particular, provided herein are fully human monoclonal antibodies against human CLPTM1L/CRR9 protein and methods of using such antibodies for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1L/CRR9 protein dysfunction (e.g., pathogenic production, modification, or function).


Find Patent Forward Citations

Loading…